Categories


Keep up to date

Search

Links


Archive


BioMed Central Blog

Friday Jan 29, 2010

How to publish raw clinical data: guidelines from Trials and the BMJ

An increasing number of peer-reviewed journals and research funding agencies require authors to make available the raw, unprocessed data supporting the findings reported in their research articles (click here for information on why this is important). Just this month, for example, The American Naturalist announced that its authors must make their data publicly available as a condition of publication and the UK Government has also recently launched an open data website.

But there is little practical guidance available on how data should be shared, particularly in clinical research where sharing information about individuals without their consent presents risks to privacy - both from a legal and ethical perspective.

Recognizing this problem, in March 2009 the editors of the journal Trials made a committment to produce guidance on preparing raw clinical data for publication.

"Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers" - co-published today in Trials and in the BMJ - represents that guidance. It proposes a minimum standard for anonymizing (or "de-identifying") datasets to protect patient privacy whilst allowing clinical data to be shared.

Research article
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers
Iain Hrynaszkiewicz, Melissa L Norton, Andrew J Vickers, Douglas G Altman
Trials 2010, 11:9 (29 January 2010)
[Abstract] [PDF]

The guidance lists 28 items of personal and clinical information that can make patients identifiable and recommends that any direct identifiers, such as patients' names and addresses, should be removed from datasets before publication. Unless patients have consented to the sharing of their data, datasets containing three or more indirect identifiers, such as age or sex, should be reviewed by an independent researcher or ethics committee to determine any risks to privacy, before data are submitted for publication. If the independent review finds privacy could be at risk, alternatives to fully open access sharing of data must be considered.

Making raw clinical data available will benefit future research - and to that end, human health - and all researchers should obtain consent for sharing of supporting data when recruiting human subjects. Until this becomes a routine practice, however, concerns about patient privacy remain a common barrier to the sharing of information. This practical guidance aims to help remove this obstacle and enable other scientists and patients to benefit from full and transparent reporting of research data.


 

Post a Comment:
  • HTML Syntax: Allowed